Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | PHASE1 | COMPLETED | 64 | — | — | Sep 21, 2012 | Aug 2, 2017 | Dec 19, 2020 | 11 | United States, Belgium +7 |
Incidence of dose-limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| LJM716 in combination with trastuzumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LJM716 | DRUG | LJM716 |
| Trastuzumab | DRUG | Trastuzumab |
Inclusion Criteria: * Patients with confirmed HER-2 positive, metastatic or non-operable locally advanced breast or gastric cancer * Metastatic breast cancer patients must have received a minimum of 1 and a maximum of 3 prior anti HER2 based regimens with documented progression on the most recent r...